Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NanoSonic Products, a wholly owned subsidiary of CTD Holdings, has signed a manufacturing agreement with Florida Biologix for the production of the sterile liquid form of its Trappsol Cyclo product.
Subscribe to our email newsletter
Trappsol Cyclo product is an orphan drug-designated treatment for Niemann Pick Type-C disease, also known as Childhood Alzheimer’s.
The product is currently being administered in the US under a compassionate use IND, the company said.
NanoSonic Products president and CEO Jeffrey Tate said manufacturing of the liquid form of their Trappsol Cyclo is the first step in their stability testing project for this product.
"Obtaining stability data for this form of our product is a top priority, and the opportunity to work with Florida Biologix’s manufacturing experts will move it forward quickly," Tate added.